

A CLINICAL STUDY TO EVALUATE THE EFFICACY OF A POLY HERBAL FORMULATION (VIGOR-100-STAMINA) IN THE MANAGEMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

Dash Deba Prasad¹, Nayak Saurabha², Sahu Sushanta³

¹HOD, Dept of Panchakarma, ²Ph.D Scholar, Dept of Kayachikitsa, ³P.G. Scholar, Dept of Kayachikitsa, Gopabandhu Ayurveda Mahavidyalaya, Puri, Odisha, India

ABSTRACT

“Hypoactive Sexual Desire Disorder (HSDD)” is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. Additionally, anxiety can also impact sexual function. Certainly, marital discord or relationship disharmony, can also take its toll on sexual desire. There are no such drugs in modern medicine to develop sexual desire in human being but the ancient treaties of *Ayurveda* describe some drugs under aphrodisiac categories which develop the sexual desire as well as potency. In this clinical trial 50 patients were taken with the symptoms of HSDD with low Serum testosterone level and divided in two groups, i.e. - Trial group and Placebo group following the criteria for selection. The poly herbal formulation namely “Vigor-100 Stamina” capsule was given to trial group and placebo capsule to the placebo group for a period of 6 weeks. The result was evaluated by increase in serum testosterone level and two standard questionnaires methods. It was found that Vigor-100 Stamina was very much effective in the management of HSDD without causing any adverse effect.

Keywords: *Hypoactive Sexual Desire Disorder, Vigor-100 Stamina, Ayurveda, Serum Testosterone.*

INTRODUCTION

The words “Hypoactive Sexual Desire Disorder (HSDD)” is defined by the American Psychiatric Association as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. For a diagnosis of HSDD to be given, the desire problem must not be better accounted for by another psychiatric disorder (e.g., depression), substance (e.g., a medication), or medical condition ^[1]. There are many risk factors and causes associated with Hypoactive Sexual Desire Disorder. If we consider sexual health and function from a holistic perspective, it is not surprising that mental health disorders, and physical ailments, can cause sexual dysfunction. In

terms of mental illness, an actual symptom of depression is loss of interest in activities that were previously enjoyed, one of which can be sex. Additionally, anxiety can also impact sexual function. Certainly, marital discord or relationship disharmony, can also take its toll on sexual desire. There are no such drugs in modern science to develop sexual desire in human being but the ancient treaties of *Ayurveda* describe some drugs under aphrodisiac categories which develop the sexual desire as well potency. The trial drug poly herbal compound (Vigor-100-Stamina) having such potency, containing some aphrodisiac drugs like- *Kapikachhu, Shilajit, Musahli, Ashwagandha, Samudra-Sosha, Jaiphala, Jaipatri, Dalchini, Akara-*

kara, Lavanga, Keshara, Louhabhasma and Swarnabhasma etc. and processed by triturating with Brahmi, Yasthimadhu, Chandan, Satavari and Tambula swarasa.

EPIDEMIOLOGY & PREVALENCE OF HSDD: In 1999, The National Health and Social Life Survey (NHSLs) assessed sexual functioning among men and women in the U.S. The survey reported that 43% of women experienced some type of sexual dysfunction compared to only 31% of men [2]. In two sexual studies it was found that, in women, the most common complaint was low sexual desire (22% & 27 % respectively) [3, 4]. In 2005, The Global Study of Sexual Attitudes and Behaviors (GSSAB) found similar results in a larger-scaled international survey of sexual problems among men and women in between 40 to 80 years of age. The GSSAB found that 26% to 43% of experienced low sexual desire compared to 13% to 28% of men (Gingell et al., 2005).

Drug Review

1. Kapikachhu (<i>Mucuna prurita</i>) –	148 mg. Ref- API, Vol-2 , P.g-46
2. Sodhita Silajatu (<i>Asphaltum punjabinum</i>)	50 mg. Ref- Bhabaprakash, Pg-370
3. Sweta Mushali (<i>Chlorophytum borivillanum</i>)	75 mg. Ref- Bhabaprakash, pg-391
4. Ashwagandha (<i>Withania somnifera</i>)	60 mg. Ref-API, Vol-1 , Pg.-15
5. Dalchini (<i>Cinamomum zeylanicum</i>)	15 mg. Ref- Bhabaprakash, pg-118
6. Samudra sosha (<i>Barringtonia acutangula</i>)	20 mg. Ref- Bhabaprakash, pg-232
7. Salam mishri (<i>Eulophia campestris</i>)	20 mg. Ref- Bhabaprakash, pg-542
8. Jaiphal (<i>Myristica fragrans</i>)	15 mg. Ref- Bhabaprakash, pg-111
9. Jaipatri (<i>Myristica fragrans</i>)	15 mg. Ref- Bhabaprakash, pg-113
10. Akarakara (<i>Anacyclus pyrethrum</i>)	15 mg. Ref- Shaligram Nig., pg-37
11. Lavanga (<i>Syzygium aromaticum</i>)	15 mg. Ref- API, Vol- 1 , Pg- 80
12. Kesara (<i>Crocus sativus</i>)	6 mg. Ref- API, Vol- 4 , Pg- 52
13. Kantalouha Bhasma (oxide of iron)	6 mg. Ref- Ay. Sara Samg., pg-158
14. Swarna Bhasma (oxide of gold)	1 mg. Ref- Siddha Yogasamg. Pg-15
All these drugs are processed in:-	
1. Brahmi (<i>Bacopa monieri</i>)	q.s. Ref-API, Vol-2, Pg- 25
2. Salmali Twak (<i>Salmalia malabarica</i>)	q.s. Ref-API, Vol-3, Pg- 183
3. Shatavari (<i>Asparagus racemosus</i>)	q.s. Ref-API, Vol-4, Pg- 108
4. Nagavalli (<i>Piper beetle</i>)	q.s. Ref-API, Vol-3, Pg-131
5. Yasthimadhu (<i>Glycyrrhiza glabra</i>)	q.s. Ref-API, Vol-1, Pg- 127
6. Sweta Chandana (<i>Santalum alba</i>)	q.s. Ref-API, Vol-3, Pg- 207

MATERIALS AND METHOD

The trial drug is a “poly herbal compound (Vigor-100-Stamina capsule)” manufactured by Goodcare Pharma Pvt. Ltd., Bagi Mouza, Bishnupur, 24 Parganas and approved by Directorate of ISM Drugs control, Dept. Of Health & F.W. Govt. of West Bengal and supplied by Goodcare Pharma Pvt. Ltd. 1-Gupta Lane, Kolkata-700006. The Trial drug Vigor-100 Stamina Contains 14 nos. of natural ingredients (Herbo-mineral origin) and processed by triturating in 6 juice and decoctions.

All the drugs present in the trial drugs are having *Vajikara* (Aphrodisiac), *Rasayan* (Rejuvenation) and *Soumanasya Janana* (Pleasant for Mind) properties and after triturating with the specify juice and decoction its properties enhances.

Each capsule contain-

Patients attending the OPD & IPD of Gopabandhu Ayurveda Mahavidyalaya&

Hospital, Puri, Odisha were screened for their Serum testosterone irrespective of their sex, religion, cast etc. Only those patients who fulfilled the inclusion criteria and were ready to give informed consent for the study were registered for the trial. A specially designed research case sheet was used for collecting and maintaining different data. 40 patients were randomly allocated to the Trial group (TG) and were treated with the trial drug (Vigor-100 Stamina capsule) for a period of 6 weeks. 10 patients were also randomly allocated to the Placebo group (PG) and were treated with the Placebo (wheat powder). Randomization was done by computerized Random number generator. The entire study was completed in a span of six months (August 2014 to January 2015).

SELECTION CRITERIA

INCLUSION CRITERIA

- Age- 35 - 55 years
- Legally married and having own sexual partner
- Sex- From both the sexes
- Patient having the sign and symptoms of HSDD causing interpersonal distress. Like:-
 - i) Loss of Frequency
 - ii) Loss of Desire
 - iii) Loss of orgasm
 - iv) Loss of ability
- Patients must be willing to provide informed consent.

EXCLUSION CRITERIA

- Age below 35 years and above 55 years
- Patient having any other systemic disorder and history of STD.
- Patient having diabetes and heart diseases.
- Patients having any other Endocrine disorder.
- After menopause.

INVESTIGATION: All patients were investigated for their Fasting Blood Sugar

(FBS), Postprandial Blood Sugar (PPBS), Renal function test, Liver Function Test and Serum testosterone before starting and after the completion of the trial. All the tests were performed in NABL accredited laboratory.

STUDY DESIGN: The current study was design in two groups Group - A (Trial group) and Group - B (Placebo group). The study was started after obtaining the approval of the Institutional Ethical Committee (IEC). Informed written consent was obtained from every patient before registering them in to the trial.

DRUGS AND POSOLOGY: Trial Drug group: Vigor-100 Stamina Capsule was orally administered to the patients in the trial group in a dose of 2 capsules twice in a day after principal meal followed by lukewarm milk for a period of 6 weeks.

Placebo Drug group: 2 Placebo capsules (Wheat powder) were orally administered to the patients of control group twice in a day after principal meal followed by lukewarm milk for a period of 6 weeks.

ASSESSMENT OF THE STUDY

Criteria of Assessment

The following objective and subjective criteria were followed to assess the improvement of the cases before and after treatment. Serum testosterone, NSS ^[5] and SDI-2 ^[6] Scoring was done for every patient included in the trial before starting and after completion of the study. Change in these parameters were analysed to get the outcome of the study by using suitable statistical method. The normal reference range of serum testosterone was fixed as per the guideline of Medline Plus Medical Encyclopaedia (An online service provided by the U.S. National Library of Medicine & National Institutes of Health).

STATISTICAL ANALYSIS

The values of Serum testosterone, SDI-2 Scoring and NSS score before and

after treatment were compared using students paired t-test. If the p – value was found to be < .05 the result was interpreted as insignificant. If the p – value was found to be < .01 the result was interpreted as significant. If the p – value was found to be < .001 the result was interpreted as extremely significant. All the calculations were done by using Graph pad statistical software. The overall benefit of the drug was assessed by a specially designed scoring system. A percentage change in before treatment (BT) & after treatment (AT) was calculated for Serum testosterone, SDI-2 Scoring and NSS scale for every patient. A corresponding score equal to the percentage change was assigned for each observation. These indi-

vidual scores were added to get a total score. The total score was interpreted as per the following.

Scores ≥ 100 – Excellent Result, Scores between 61 & 100 – Good Result, Scores between 21 & 60 – Satisfactory Results, Scores ≤ 20 – Unsatisfactory Result

OBSERVATION & RESULT: We registered 40 patients in Trial Group (TG) & 10 patients in placebo group (PG). But there was a drop out of 2 patients from TG due to different reasons and all patients of PG completed their treatments. Therefore 38 patients from TG and 10 patients from PG completed the trial.

DEMOGRAPHIC DATA

1. Sex Wise Distribution of Patient

Sex	Trial (N=38)		Placebo (N=10)	
	No.	%	No.	%
Male	31	81.56	5	50
Female	7	18.44	5	50

2. Age group wise distribution of Patient

Age group in years	Trial (N=38)		Placebo (N=10)	
	No.	%	No.	%
30-40	14	36.84	3	30
40-50	14	36.84	5	50
50-60	10	26.22	2	20

3. Addiction Wise Distribution of Patient

Addiction	Trial (N=38)		Placebo (N=10)	
	No.	%	No.	%
No	14	36.84	6	60
Alcohol	6	15.79	1	10
Tobacco	16	42.11	1	10
Others	2	05.26	2	20

4. Occupation Wise Distribution of Patient

Occupation	Trial (N=38)		Placebo (N=10)	
	No.	%	No.	%
Labourer	7	18.42	0	0
Executive	18	47.36	3	30
House work	5	13.57	5	50
Business	8	21.05	2	20

5. Socio-economic status Wise Distribution of Patient

Socio-economic status	Trial (N=38)	Placebo (N=10)
-----------------------	--------------	----------------

	No.	%	No.	%
High	4	10.52	2	20
Medium	25	65.78	7	70
Low	9	23.68	1	10

EFFECTIVENESS OF TRIAL DRUG AND PLACEBO

Trial Drug:-

Parameter	Frequency (n)	Degree of Freedom (df)	BEFORE TREATMENT (BT)		AFTER TREATMENT (AT)		↑	↓	t - Value	p - Value	Interpretation
			Mean (BT)	Standard Deviation (SD)	Mean (AT)	Standard Deviation (SD)					
SDI - 2 Score	38	37	38.82	6.22	63.34	6.75	↑	33.73	< 0.0001	Extremely Significant	
NSS Score	38	37	41.34	6.25	67.63	5.86	↑	41.96	< 0.0001	Extremely Significant	
Serum Testosterone (ng/dL)	38	37	344.67	185.88	525.99	255.33	↑	3.54	0.0007	Extremely Significant	

Placebo :-

Parameter	Frequency (n)	Degree of Freedom (df)	BEFORE TREATMENT (BT)		AFTER TREATMENT (AT)		↑	↓	t - Value	p - Value	Interpretation
			Mean (BT)	Standard Deviation (SD)	Mean (AT)	Standard Deviation (SD)					
SDI - 2 Score	10	9	39.50	8.83	39.90	8.88	↑	1.31	0.2229	Not Significant	
NSS Score	10	9	43.70	6.60	43.80	7.05	↑	0.43	0.6783	Not Significant	
Serum Testosterone (ng/dL)	10	9	269.86	276.98	269.94	277.41	↑	0.17	0.8669	Not Significant	

OVERALL ASSESSMENT OF TRIAL DRUG AND PLACEBO

8. Overall Assessment of results after treatment				
Overall Assessment	Trial Group		Placebo Group	
	No. of Patients	Percentage	No. of Patients	Percentage
Excellent	30	79%	0	00%
Good	6	16%	0	00%
Satisfactory	2	05%	3	30%
Unsatisfactory	0	00%	7	70%

ASSESSMENT OF ADVERSE EFFECT OF TRIAL DRUG AND PLACEBO: No adverse effect was found in both trial and placebo group during and after treatment.

OBSERVATION HIGHLIGHTS

- The study included both male (36 nos.) and female (12 nos.) patients. But males dominated female patients.
- The Study included patients in the age limit of 30 to 60 years (both inclusive). Patients in the age group of 41 – 50

years were maximum (14 & 5) and in the age group of 50 – 60 years were minimum (10 & 2) both in TG & PG.

- HSDD was found to be well distributed among different occupation. However patients with Executive and intellectual field work were found to be maximum (18 nos.) in TG & people with House work were found to be maximum (5 nos.) in PG.
- HSDD affect all types of Socio-economic classes of population Medium class being the maximum (65.78% in TG & 70% in PG) followed by low and high classes.
- It was alarming that 5.26 % patients in the TG and 20 % patients in the PG were having some or the other addiction. However Tobacco (42.11% in TG) users were maximum followed by No addiction and alcohol users.
- Vigor-100 Stamina (Trial Drug) was found effective in increasing the SDI-2 score from 38.82 to 63.34 and the results was found to be extremely statistically significant ($p < 0.0001$). But the Placebo drug was not effective in increasing the SDI-2 score from 39.50 to 39.90 and the result was insignificant (p –value, 0.2229).
- Vigor-100 Stamina (Trial Drug) was found effective in increasing the NSS score from 41.34 to 67.73 and the results was found to be extremely statistically significant ($p < 0.0001$). But the Placebo drug was not effective in increasing the NSS score from 43.70 to 43.80 and the result was insignificant (p –value, 0.6783).
- Vigor-100 Stamina (Trial Drug) was also found effective in increasing the Serum Testosterone level from 344.67 ng/dl to 525.99ng/dl and the results was found to be extremely statistically sig-

nificant ($p < 0.0007$). But the Placebo drug was not effective in increasing the Serum Testosterone level from 269.86ng/dl to 277.41ng/dl and the result was insignificant (p –value, 0.8669).

- It also increase the desire, frequency, quality of orgasm and ability in the trial group as follows-
 - 93 % of the subjects in the Trial Group (TG) experienced significantly increased libido by the completion of therapy.
 - 82 % of the subjects were having increased frequency of sexual activity as compared to the “Before Treatment” phase.
 - 91 % of the subjects experienced greater intensity of sexual arousal during and after completion of the therapy.
 - 89 % of the male subjects had better erection during sexual events.
 - 95 % of the subjects experienced a reasonably satisfying duration of sexual activity.
 - 90 % of the subjects reported a much better quality of orgasm.
 - 97 % of the subjects experienced a better mood after completion of sexual activity.
 - 86 % of the subjects were able to create a balance between what they gave and what they received from their partner during sexual act.
- On overall assessment of the effectiveness of Vigor-100 stamina & Placebo in HSDD we got the following results Vigor-100 stamina gave Excellent results in 79 % cases, Good result in 16 % cases, Satisfactory results in 5 % cases and Unsatisfactory results in 00 % cases where as Placebo gave excellent results in 00 % cases, Good result in 00 % cases, Satisfactory results in 30 % cases and Unsatisfactory results in 70 % cases.

- On analysing the incidence of adverse effects we got, Neither Vigor-100 Stamina nor does the Placebo produce any adverse effect. So the trial is safe without any complication and with a successful result.

DISCUSSION

The male patients dominated the female patients in the study. This may be due to the reasons that males are more addicted to tobacco & alcohol and their addiction is more conducive for stress and result in Hypo active Sexual Desire Disorder (HSDD). Since in the state like Odisha males get better medical facility than females, their foot-fall might have been more during the trial period also female may not come to physician for this disease as they may feel shy to communicate this. Small sample size may be a cause that female patients are less in numbers. Patients in the age group of 40 – 50 were maximum in the trial indicating that HSDD is more prevalent in this age group. This may be due to the fact that these years in life are more stressful years due to late marriage and also due to joint family they may not give sufficient time for sexual activity. So there is every chance of altered dietary habits and getting addicted to tobacco or alcohol which might have facilitated the progression of HSDD. The Executive peoples and people with intellectual field work were more in number in this trial. Their Stressful life style (as they are not satisfied in their job) may be held responsible for accelerating HSDD. Most of the patients were having addiction of Tobacco and alcohol. High incidence of tobacco & alcohol users proves that these are potential risk factors for HSDD. Medium socio-economic people are more prone for HSDD as they cannot fulfil the all needs properly and having stress in life. As stress is the prime factor, so they are attribute to HSDD. Vigor-

100 Stamina (Trial Drug) was found effective in increasing the SDI-2 score, NSS Score and Serum Testosterone level as compare to the Placebo drug. Trial Drug increases all the criteria remarkable but Placebo increase very less or negligible. However the little change is due to the effect of Patients counselling, education and effect of the Placebo. The overall effect of Vigor-100 Stamina and Placebo can't be comparable as Vigor-100 Stamina shows remarkably excellent result but the Placebo shows only satisfactory effects in few cases. As per safety profile, both are safe without any adverse effect and any organic effects like altered liver function and renal functions. Considering the effectiveness both Vigor-100 Stamina and Placebo in managing HSDD, we can say that the former has greater effect over the later. Vigor-100 Stamina has unique ability to manage HSDD without causing any adverse effect or deleterious effect on the vital organs.

Possible Mode of Action of Vigor-100

Stamina: The trial drug poly herbal compound (Vigor-100 Stamina) having such potency containing some aphrodisiac drugs like- *Kapikachhu, Shilajit, Mushali, Ashwagandha, Samudrasosha, Jaiphala, Jaipatri, Dalchini, Akarakara, Lavanga, Keshara, Louhabhasma and Swarnabhasma* etc. and processed by triturating with *Brahmi* juice, *Mulethi* decoction, *Chandan* decoction, *Shatavari* juice and *Tambula* juice. *Kapikachhu, Akarakara, Jaipatri, Shilajit, Mushali, Samudrasosha and Keshar* are having aphrodisiac properties which might be able to enhance the serum testosterone level [7, 8, 9, 10, 11]. These individual drugs have also proven earlier as aphrodisiac by various experimental and human trials. The drugs like *Ashwagandga, Swarna bhasma, Shatavari, Mulethi, Brahmi* are very much effective in case of stress and stress related

disorders^[12]. As the disease HSDD is mainly related to stress, therefore these drugs help managing HSDD successfully. Precisely it can be said that Vigor-100 Stamina is very effective by the synergetic actions of all these drugs together.

CONCLUSION

As per the results of this study, Vigor-100 Stamina (Trial Drug) was found effective in increasing the SDI-2 score, NSS Score and Serum Testosterone level as compared to the Placebo. Vigor-100 Stamina was found effective in all the parameters with statistical significance where as the results of the placebo were negligible with no statistical significance. The trial drug also improved all other criteria like frequency of sexual events, quality of orgasm, ability and desire as compared to the placebo. Since Vigor-100 Stamina doesn't produce any adverse effects, therefore Vigor-100 Stamina would definitely be an effective and safe choice in managing Hypoactive Sexual Desire Disorder (HSDD).

REFERENCES

1. Dorland's Medical Dictionary for Health Consumers. 2007 by Saunders, an imprint of Elsevier.
2. http://www.cdc.gov/nchs/data/ahcd/namcs_summary/2009_namcs_web_tables.pdf. Last accessed on 7th. March 2015.
3. Sheryl A. Kingsberg, PhD, *The Female Patient* | Vol 36 MARCH 2011, 1
4. Molly Katz et.al-Efficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA Trial:- 2013 International Society for Sexual Medicine
5. The Journal of Sex Research:- Development and Bi-Cultural Validation of the New Sexual Satisfaction Scale
6. Spector, I. P., Carey, M. P., & Steinberg, L. (1996). The Sexual Desire Inventory: Development, factor structure, and evi-

dence of reliability. *Journal of Sex and Marital Therapy*, 22, 175–190.

7. Sunjay Kumar Garg:-Clinical Evaluation of Tentex Royal in Erectile Dysfunction.
8. Qureshi S, Shah AH, Tariq M. and Ageel AM. (1989). Studies on herbal aphrodisiacs used in arab system of medicine. *Am. J. Chin. Med.*, 17(1-2), 57.
9. Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. *Fertil Steril*. 2007; 87(1):107-112.
10. Triparhy R.D., Sharangadhar Samhita
11. Chunekar K.C., Bhabaprakash Nighantu
12. Ayurvedic Pharmacopia of India:- Vol-1 to 4

CORRESPONDING AUTHOR

Dr Saurabha Nayak

C/o – Chhayakanta Nayak

Krishnananda Matha Lane, Balighat

Puri-2, Odisha, India. PIN - 752002

Email:dr_sourav78@yahoo.co.in

ACKNOWLEDGEMENT

The authors are thankful to **M/s Goodcare Pharma Pvt. Ltd, 1, Gupta Lane, Calcutta (INDIA) - 700 006** for providing Trial Drug, Placebo and financial assistance for this research project.

Source of support: Nil

Conflict of interest: None Declared